Trials / Completed
CompletedNCT04167761
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ertugliflozin | Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2019-11-19
- Last updated
- 2024-12-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04167761. Inclusion in this directory is not an endorsement.